Indoco Remedies' Goa facility receives UK-MHRA nod

Mumbai, Mar 28 (UNI) Pharma major Indoco Remedies Ltd has successfully completed the MHRA UK audit of its Goa facility for tablets, creams, ointments and capsules.

A press release issued here today stated that the nod extends to the ''pilot facility'' in the new tablet area. With approval of this pilot plant, Indoco will be in a position to conduct validation batches for clinical trials for products to be registered in Europe.

Indoco Remedies Chairman and Managing Director Suresh Kare said, ''We successfully completed the audit of our new tablet facility as well as its capsules and semi-solids line. This demonstrates confidence by the international regulatory bodies in our manufacturing capabilities and strengths. This is a right step in the direction of achieving our vision of becoming a 1,000-crore company by 2010.'' Indoco Remedies Limited is a fast growing Indian company involved in research and development, manufacturing, marketing and distribution of pharmaceutical products and services in the domestic and international market.

Indoco has five manufacturing facilities - two in Goa, two in Mumbai, and a plant in Baddi (Himachal Pradesh).

Indoco manufactures and markets as many as 50 pharmaceutical formulations across a wide spectrum of therapeutic groups ranging from anti-spasmodics, anti-cold preparations, cough syrups, anti-fungals, NSAIDs, anti-infectives, antibiotics, anti-tuberculars, anti-malarials, etc. both in the domestic and international markets.

The company has recently made a foray into the super-specialty segment such as cardiology, diabetology and life-style segments, pointed out the release.

UNI JJ KU SKB1720